Trial Profile
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisolone; Prednisone; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Celgene Corporation; Celgene International SARL
- 19 Aug 2022 Status changed from active, no longer recruiting to completed.
- 17 Jul 2022 This trial has been completed in Austria ,according to European Clinical Trials Database record.
- 01 Feb 2022 Results published in the International Journal of Hematology